NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

Health Technology Appraisal

Oxaliplatin and capecitabine for the adjuvant treatment of colorectal cancer

Provisional matrix of consultees and commentators

| Consultees | | Commentators (no right to submit or appeal) | |
|------------------------|---|---|---|
| Manufacturers/sponsors | | Ge | eneral |
| | ne Products Ltd (capecitabine) | • | Board of Community Health Councils in |
| | ofi-Synthelabo (oxaliplatin) | | Wales |
| | , , , | • | British National Formulary |
| Patient/carer groups | | • | National Collaborating Centre for Acute |
| | ing Bowel Cancer | | Care |
| • Cano | cer Voices | • | National Public Health Service for |
| • Cano | cerBACUP | | Wales |
| Colo | n Cancer Concern | • | NHS Confederation |
| • COR | E (Digestive Disorders | • | NHS Purchasing and Supplies Agency |
| Foun | ndation) | • | NHS Quality Improvement Scotland |
| Long | -term Medical Conditions | | |
| Alliar | nce | <u>Cc</u> | mparator manufacturers |
| | 's Bowel Cancer Campaign | • | Mayne Pharma plc (fluorouracil) |
| Macr | millan Cancer Relief | • | Medac UK (fluorouracil) |
| | e Curie Cancer Care | • | Wyeth Pharmaceuticals (calcium |
| | onal Cancer Alliance | | levofolinate) |
| | onal Council for Hospice and | D - | lavant na a analy mayora |
| | cialist Palliative Care Services | | elevant research groups |
| | nage Cancer Trust | • | Institute of Cancer Research |
| • Tend | ovus Cancer Information Centre | • | MRC Clinical Trials Unit |
| Dueteesia | and anatoms | • | National Cancer Research Institute |
| | Professional groups | | sessment team |
| | ciation of Cancer Physicians | <u>∧s</u> | National Coordinating Centre for Health |
| | sh Oncological Association | | Technology Assessment |
| | h Oncology Pharmacy | • | School of Health & Related Research |
| | sociation (BOPA) | | Sheffield |
| | h Psychosocial Oncology ciety (BPOS) | | |
| | cer Research UK | | |
| | al College of General | | |
| | titioners | | |
| | al College of Nursing | | |
| | al College of Pathologists | | |
| | al College of Physicians' Medical | | |
| | cology Joint Special Committee | | |

National Institute for Clinical Excellence Consultation on the draft scope for the appraisal of Oxaliplatin and capecitabine for the adjuvant treatment of colorectal cancer Issue date: November 2004

| Royal College of RadiologistsRoyal College of SurgeonsRoyal Pharmaceutical Society | |
|--|--|
| Others | |
| Department of Health | |
| South Gloucestershire PCT | |
| South Leicestershire PCT | |
| Welsh Assembly Government | |

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, the *British National Formulary*, and the British Medical Association.

Assessment team

An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).